153 related articles for article (PubMed ID: 19138959)
1. Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial".
Stevens RG; Pretlow TP; Hurlstone DP; Giardina C; Rosenberg DW
Cancer Prev Res (Phila); 2008 Aug; 1(3):215-6; author reply 216. PubMed ID: 19138959
[No Abstract] [Full Text] [Related]
2. Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention.
Lance P; Hamilton SR
Cancer Prev Res (Phila); 2008 Jun; 1(1):4-8. PubMed ID: 19138929
[No Abstract] [Full Text] [Related]
3. Aberrant crypt foci in the adenoma prevention with celecoxib trial.
Cho NL; Redston M; Zauber AG; Carothers AM; Hornick J; Wilton A; Sontag S; Nishioka N; Giardiello FM; Saltzman JR; Gostout C; Eagle CJ; Hawk ET; Bertagnolli MM
Cancer Prev Res (Phila); 2008 Jun; 1(1):21-31. PubMed ID: 19138933
[TBL] [Abstract][Full Text] [Related]
4. Screening for colorectal cancer: does it all start with aberrant crypt foci?
Rasheed S; Rigas B
Gastrointest Endosc; 2008 Jun; 67(7):1103-5. PubMed ID: 18513552
[No Abstract] [Full Text] [Related]
5. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia.
Hurlstone DP; Karajeh M; Sanders DS; Drew SK; Cross SS
Am J Gastroenterol; 2005 Jun; 100(6):1283-9. PubMed ID: 15929758
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis in the colonic crypt, colorectal adenomata, and manipulation by chemoprevention.
West NJ; Courtney ED; Poullis AP; Leicester RJ
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1680-7. PubMed ID: 19505899
[TBL] [Abstract][Full Text] [Related]
7. Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory?
Lynch PM
Gastroenterology; 2006 Dec; 131(6):2003-5. PubMed ID: 17188962
[No Abstract] [Full Text] [Related]
8. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.
Hosono K; Endo H; Takahashi H; Sugiyama M; Sakai E; Uchiyama T; Suzuki K; Iida H; Sakamoto Y; Yoneda K; Koide T; Tokoro C; Abe Y; Inamori M; Nakagama H; Nakajima A
Cancer Prev Res (Phila); 2010 Sep; 3(9):1077-83. PubMed ID: 20810669
[TBL] [Abstract][Full Text] [Related]
9. Early events in human colorectal carcinogenesis. Aberrant crypts and microadenoma.
Roncucci L
Ital J Gastroenterol; 1992; 24(9):498-501. PubMed ID: 1489980
[TBL] [Abstract][Full Text] [Related]
10. Aberrant crypt foci and beta-catenin accumulated crypts; significance and roles for colorectal carcinogenesis.
Mori H; Yamada Y; Kuno T; Hirose Y
Mutat Res; 2004 May; 566(3):191-208. PubMed ID: 15082237
[TBL] [Abstract][Full Text] [Related]
11. Aberrant crypt foci in patients with a positive family history of sporadic colorectal cancer.
Stevens RG; Swede H; Heinen CD; Jablonski M; Grupka M; Ross B; Parente M; Tirnauer JS; Giardina C; Rajan TV; Rosenberg DW; Levine J
Cancer Lett; 2007 Apr; 248(2):262-8. PubMed ID: 16950561
[TBL] [Abstract][Full Text] [Related]
12. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
13. The natural history of aberrant crypt foci.
Schoen RE; Mutch M; Rall C; Dry SM; Seligson D; Umar A; Pinsky P
Gastrointest Endosc; 2008 Jun; 67(7):1097-102. PubMed ID: 18178205
[TBL] [Abstract][Full Text] [Related]
14. Aberrant crypt foci: are they intermediate endpoints of colon carcinogenesis in humans?
Gupta AK; Schoen RE
Curr Opin Gastroenterol; 2009 Jan; 25(1):59-65. PubMed ID: 19114775
[TBL] [Abstract][Full Text] [Related]
15. [Non-steroidal anti-inflammatory agents and prevention of colorectal adenomas and carcinomas].
Raskov HH
Ugeskr Laeger; 2006 Jan; 168(4):359-62. PubMed ID: 16436235
[No Abstract] [Full Text] [Related]
16. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress.
Hawk E; Viner JL
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):185-7. PubMed ID: 17301246
[No Abstract] [Full Text] [Related]
17. Chemoprevention of colorectal cancer.
Niitsu Y; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Kukitsu T; Takanashi K; Ishiwatari H; Abe T; Kogawa T; Takahashi M; Matsunaga T; Kato J
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S40-3. PubMed ID: 15309513
[TBL] [Abstract][Full Text] [Related]
18. Intermediate effect markers for colorectal cancer.
Baron JA
IARC Sci Publ; 2001; 154():113-29. PubMed ID: 11220651
[TBL] [Abstract][Full Text] [Related]
19. New, long-term insights from the Adenoma Prevention with Celecoxib Trial on a promising but troubled class of drugs.
Dubois RN
Cancer Prev Res (Phila); 2009 Apr; 2(4):285-7. PubMed ID: 19336723
[No Abstract] [Full Text] [Related]
20. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Solomon SD; Pfeffer MA; McMurray JJ; Fowler R; Finn P; Levin B; Eagle C; Hawk E; Lechuga M; Zauber AG; Bertagnolli MM; Arber N; Wittes J;
Circulation; 2006 Sep; 114(10):1028-35. PubMed ID: 16943394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
